It’s a problem that has plagued European governments for decades, from the credit-crunch bank bailouts of 2008 to more recent ...

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will summarize the bulls’ thesis on NVO.

Novo Nordisk on Wednesday reported better ... and diabetes drugs continued to soar. The maker of weight loss drug Wegovy and ...

Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...

The top 20 biopharmaceutical companies experienced mixed performance in 2024 amid a dynamic landscape influenced by various ...

Although RMD has re-rated from its share price low of around $21.50 in October 2023, it has only just surpassed its all-time ...

More than half of adults with overweight or obesity prescribed a GLP-1 discontinue their drug within 1 year, with discontinuation rates higher for those without type 2 diabetes, researchers reported ...

Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...

A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs like Ozempic, Wegovy and ...

These compounds take a different approach to weight loss than existing medications, which can cause nausea, vomiting and ...